TCM
ANIP icon

Triarii Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Triarii Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$3.67M Buy
65,000
+25,000
+63% +$1.53M 3.75% 12
2018
Q2 		$2.67M Hold
40,000
– – 2.5% 15
2018
Q1 		$2.33M Sell
40,000
-10,936
-21% -$694K 2.69% 16
2017
Q4 		$3.28M Buy
+50,936
New +$3.17M 3.57% 14

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Triarii Capital Management's ANIP Position: Q3 2018 in Review

Triarii Capital Management increased its ANI Pharmaceuticals (ANIP) stake by 63% in Q3 2018, buying an estimated $1.53M and bringing the position to 65,000 shares worth $3.67M. The position accounts for 3.75% of the portfolio, ranked #12.

Triarii Capital Management first reported a position in ANIP in Q4 2017 and has held it in 4 quarters since. 173 funds tracked by Wall St. Rank hold ANIP as of Q3 2018.

  • Triarii Capital Management held 65,000 shares of ANI Pharmaceuticals worth $3.67M as of Q3 2018.
  • Triarii Capital Management bought 25,000 ANI Pharmaceuticals shares in Q3 2018, an estimated $1.53M.
  • ANI Pharmaceuticals made up 3.75% of Triarii Capital Management's portfolio in Q3 2018, its #12 holding.
  • Triarii Capital Management first reported a position in ANI Pharmaceuticals in Q4 2017 and has held it in 4 quarters since.
  • 173 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2018.

Based on Triarii Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.